Drugs that contain Radium Ra-223 Dichloride
1. Xofigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6635234 | BAYER HLTHCARE | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
Jan, 2020
(4 years ago) | |
| US8791127 | BAYER HLTHCARE | Mucosal bioadhesive slow release carrier for delivering active principles |
Mar, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2018 |
NCE-1 date: 15 May, 2017
Market Authorisation Date: 15 May, 2013
Treatment: Therapeutic treatment of bone metastases
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
XOFIGO family patents
